Pharmacy Guide

Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.

Pharmacy Guide

Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.

← Back to all medicines

Hytrin 10mg Tablets

⚠ This medicine appears to have been discontinued

The electronic medicines compendium (emc) no longer publishes a Summary of Product Characteristics for this product, which usually means it is no longer marketed in the UK. The patient leaflet below is kept for reference, but the product may not be available.

If you were prescribed this medicine, other products containing Terazosin monohydrochloride dihydrate may still be available. Do not stop your treatment — ask your pharmacist or GP what to use instead.

Active substance: Terazosin monohydrochloride dihydrate
Source: electronic medicines compendium (emc)
Official leaflet: Read the PIL on emc

What it is and what it is used for

for The name of your medicine is Hytrin 1 mg, 2 mg, 5 mg, or 10mg Tablets (called Hytrin Tablets in this leaflet). Hytrin Tablets contains the active ingredient terazosin. Terazosin belongs to a group of medicines called alpha-blockers. Hytrin Tablets are used in adults to treat high blood pressure. Hytrin Tablets are also used in adults for the treatment of a condition called benign prostatic hyperplasia (BPH) which affects the prostate and is common in older men. This condition stops the flow of urine from the bladder and can lead to symptoms such as a weak or interrupted urine flow, a need to pass water more frequently and/or a sudden need to pass water. Hytrin Tablets can relax the muscle of the prostate gland and bladder exit to help relieve these symptoms.

What you need to know before you take it

e Hytrin Tablets Do not take Hytrin Tablets

  • if you are allergic to terazosin or any of the other ingredients of this medicine listed in section 6 (allergic reactions include mild symptoms such as itching and/or rash. More severe symptoms include swelling of the face, lips, tongue and/or throat with difficulty in swallowing or breathing).
  • if you are allergic to any of the following drugs: alfuzosin, indoramin, prazosin, tamsulosin, doxazosin.
  • if you have ever fallen over or fainted while passing water. Warnings and precautions Talk to your doctor or pharmacist before taking Hytrin Tablets if you:

•are taking other medication for high blood pressure. If a medicine for high blood pressure is started whilst you are taking Hytrin Tablets, then your doctor may need to adjust your dose of Hytrin Tablets. •have any problems with your heart. •are taking medicines for erectile dysfunction (e.g. Cialis, Viagra, Levitra). •are planning cataract removal surgery. Hytrin Tablets must be used for BPH only after excluding other possible reasons in urinary tract for abnormal/ interrupted urinary flow. Hytrin Tablets can cause fainting or low blood pressure, usually after the first or first few doses. These effects can also occur if you stop taking Hytrin Tablets and then re-start. Hytrin Tablets may also lead to decreases of certain laboratory values, such as red blood cells or white blood cells. If any of the above applies to you, or if you are not sure, please tell your doctor before taking Hytrin Tablets. Children and adolescents Hytrin Tablets are not recommended for use in children. Other medicines and Hytrin Tablets Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. It is especially important to tell your doctor if you are taking;

  • other medicines to treat high blood pressure including ACE inhibitors and water tablets (diuretics);
  • medicines for erectile dysfunction (e.g. Cialis, Viagra, Levitra, Stendra). Some patients who take alpha-blocker therapy for the treatment of high blood pressure or prostate enlargement may experience dizziness or light-headedness which may be caused by low blood pressure upon sitting or standing up quickly. The medicines which cause low blood pressure with alpha blockers include  Medicines treating high blood pressure – adrenergic neurone blockers (e.g. Guanithidine),  alcohol,  cancer treating medicine (e.g. aldesleukin),  medicines for treating high blood pressure (e.g. Angiotensin – II receptor antagonists, Beta blockers, Calcium-channel blockers, Clonidine, Moxinidine, Tizanidine Diazoxide, Hydralazine, Nitrtaes, Sodium nitroprusside  medicines for treating schizophrenia (antipsychotics),  medicines for treating muscle spasm (e.g. baclofen),  anti-inflammatory drugs like corticosteroids,  medicines used for general anesthesia before surgery.  medicine used for baldness (Minoxidil)

    

medicines for treating Parkinson's condition (e.g. levodopa and Methyldopa) medicines for treating depression (MAOI's) medicines for chest pain (nitrates) pain killers female sex hormone (estrogen)

Certain patients have experienced these symptoms when taking drugs for erectile dysfunction (impotence) with alpha-blockers. These medicines include alprostadil and Moxisylyte. In order to reduce the likelihood that these symptoms occur, you should be on a regular daily dose of your alpha-blockers before you start drugs for erectile dysfunction. If you are going to have a general anaesthetic, you should tell the doctor or dentist in charge that you are taking Hytrin Tablets. If you are undergoing eye surgery because of cataract (cloudiness of the lens) please inform your eye specialist before the operation that you are using or have previously used Hytrin Tablets. This is because Hytrin Tablets may cause complications during the surgery which can be managed if your specialist is prepared in advance. Hytrin Tablets with food, drink and alcohol Hytrin Tablets can be taken with or without food Do not consume alcohol while on treatment with Hytrin as alcohol may increase the risk of dizziness, light-headedness or drowsiness. Pregnancy and breast-feeding If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine. Pregnancy Hytrin Tablets should not be used during pregnancy unless considered appropriate by your doctor. Breast-feeding It is not known whether Hytrin passes into breast milk. Driving and operating machinery It is important to avoid driving, using machinery or carrying out hazardous tasks for 12 hours after taking your first tablet of each different strength (i.e. the tablets taken on days 1, 8 and 22 of the hypertension starter pack), as dizziness, light-headedness or drowsiness may occur. Hytrin Tablets contain lactose If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicinal product.

How to take it

Hytrin Tablets Always take this medicineexactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure. For high blood pressure (hypertension) If you are taking Hytrin Tablets for the first time or if you have not taken Hytrin Tablets in the last week: It is important that you take the correct Hytrin Tablet at the correct time. You should begin taking tablets from the strip marked HYTRIN STARTER PACK. All tablets from this strip should be taken at bedtime.

Start taking your Hytrin Tablets at Day 1 marked START on the strip. This is a white tablet, and you should take it by mouth just before going to bed. You will notice that from Day 8 onwards, the tablets are yellow. This is to show that the tablets contain a different dose of Hytrin from the white tablets. Continue to take one tablet each day before you go to bed until you reach Day 14. When you have finished the strip marked HYTRIN STARTER PACK, the next tablet that you take should come from the strip which is marked HYTRIN 2 mg with the days of the week. See diagram below;

This strip is marked with the days of the week to help you remember if you have taken your tablet. For instance, if you start taking tablets from this strip on a Wednesday, take one tablet from a space marked Wednesday. Continue taking one tablet each day following the arrows on the strip until there are no tablets left. You should take your tablets at the same time each day at bedtime. If you are unsure about when to take your tablets, you should consult your doctor for advice. If you have taken Hytrin Tablets using a Starter Pack and you are continuing with your next pack: When you have finished your Starter Pack, your doctor may give you more tablets. Depending on your response to Hytrin Tablets, your doctor will decide which strength of tablet you need. You may be given a new pack of Hytrin Tablets containing either 2 mg (yellow tablets), 5 mg (tan tablets) or 10 mg (blue tablets). Whichever strength you have will be in a pack containing 2 strips of 14 tablets marked with the days of the week, as shown below.

Start the new strip by taking a tablet from the space marked with the correct day of the week, e.g., if you are starting on a Wednesday, take your first tablet from a space marked Wednesday. Continue taking one tablet each day following the arrows on the strip until there are no tablets left. You should take your tablets at the same time each day, e.g. bedtime. If you are unsure about when to take your tablets, you should consult your doctor for advice. You should continue to take your tablets unless your doctor tells you not to. Do not stop just because you feel better. For Benign Prostatic Hyperplasia (BPH)

If you are taking Hytrin Tablets for the first time or if you have not taken Hytrin Tablets in the last week: It is important that you take the correct Hytrin Tablet at the correct time. You should begin taking tablets from the strip marked HYTRIN STARTER PACK 1. All tablets from this strip should be taken at bedtime.

Start taking your Hytrin Tablets at Day 1 marked START on the strip. This is a white tablet, and you should take it by mouth just before going to bed. You will notice that from Day 8 to Day 14, the tablets are yellow. This is to show that the tablets contain a different dose of Hytrin from the white tablets. When you have finished the strip marked HYTRIN STARTER PACK 1, the next tablet that you take should come from the strip, which is marked HYTRIN STARTER PACK 2. Start taking your Hytrin Tablets at Day 15 marked START on the strip. This is a yellow tablet. When you reach day 22, the tablets are tan. This is so that you take the weakest (white) tablets for the first week, stronger (yellow) tablets in weeks 2 and 3 and the strongest (tan) tablets in the 4th week. See diagram below:

You should take your tablets at the same time each day at bedtime. If you are unsure about when to take your tablets, you should consult your doctor for advice. If you have taken Hytrin Tablets using a Starter Pack and you are continuing with your next pack: When you have finished your Starter Pack, your doctor may give you more tablets. Depending on your response to Hytrin Tablets, your doctor will decide which strength of tablet you need. You may be given a new pack of Hytrin Tablets containing either 2 mg (yellow

tablets), 5 mg (tan tablets) or 10 mg (blue tablets). Whichever strength you have will be in a pack containing 2 strips of 14 tablets marked with the days of the week, as shown below.

Start the new strip by taking a tablet from the space marked with the correct day of the week, e.g., if you are starting on a Wednesday, take your first tablet from a space marked Wednesday. Continue taking one tablet each day following the arrows on the strip until there are no tablets left. You should take your tablets at the same time each day, e.g. bedtime. If you are unsure about when to take your tablets, you should consult your doctor for advice. You should continue to take your tablets unless your doctor tells you not to. Do not stop just because you feel better. If you take more Hytrin tablets than you should If you take more Hytrin Tablets than you should, (more than one tablet in one day) contact your doctor or nearest hospital emergency department immediately. Signs of overdose include low blood pressure, dizziness, lightheadedness, fainting, a rapid or irregular heartbeat and feeling sick. Take the container and any remaining tablets with you. If you forget to take Hytrin Tablets If you forget to take a dose, just take the next dose at the usual time, DO NOT take a double dose to make up for a forgotten tablet. If you have not taken a tablet for several days you should NOT continue using the same tablets but return to your doctor for a new starter pack. If you have any further questions on the use of this medicine, ask your doctor or pharmacist.

Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them. If you notice; • Itching or skin rashes; • Swelling of your face, lips or throat; • Difficulty in breathing or wheeziness. Stop taking the medicine and seek medical advice immediately. These may be signs of an allergic reaction.

When taking Hytrin Tablets for the first time or when starting to take higher dose tablets dizziness, light-headedness or fainting may occur. These effects may also occur when standing up quickly from a lying or sitting position. If you are affected by this, you should lie down until you feel better then you should sit for a few minutes before standing again to prevent these effects returning. These side effects usually go away and should not return once you have become used to taking your tablets. Not known: frequency cannot be estimated from the available data: • low blood platelet count; • weakness, dizziness; • a fast or uneven heartbeat; • feeling sick; • swelling of the hands and feet; • asthenia (decrease in muscle strength); • sleepiness; • blocked nose; • blurred vision. • back pain, neck pain, shoulder pain; • pains in hands and feet, pins and needles; • headache; • increased heart rate, irregular heart rate; • low blood pressure (hypotension) which can cause dizziness or faintness on standing; • loss of consciousness; • dilatation of blood vessels; • weight gain; • nervousness, depression, anxiety; • shortness of breath or difficulty breathing; • decreased sex-drive, erectile dysfunction, persistent and painful erection; • vertigo (problems with balance that can result in feelings of dizziness or sickness particularly on standing); • chest pains; • facial swelling, flushing; • stomach pain, indigestion; • being sick, constipation, diarrhoea, passing wind (flatulence); • dry mouth; • inflammation or pains in joints or muscles; • difficulty sleeping; • bronchitis (inflammation of the lungs); • sinusitis (inflammation of nasal passage) • rhinitis (Irritation and swelling of the mucous membrane in the nose) • nose bleeds; • flu-like symptoms, pain and irritation of the throat, sore throat, cough; • skin rashes and itching; • sweating;

• •

vision problems and conjunctivitis; ringing in the ears; increased frequency of passing water, urinary infection, lack of bladder control; low blood cell counts, laboratory tests abnormal.

Some patients have experienced unexpected bruising and their blood taking longer than usual to clot after a cut to the skin. Reporting of side effects If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the Yellow Card Scheme, website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. By reporting side effects you can help provide more information on the safety of this medicine.

How to store it

Hytrin Tablets Do not use this medicine after the expiry date which is stated on the package. The expiry date refers to the last day of that month. Do not store above 25o C. Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help to protect the environment. KEEP THIS MEDICINE OUT OF THE SIGHT AND REACH OF CHILDREN.

Contents of the pack and other information

What Hytrin Tablets contains Hytrin Tablets come in 4 strengths and colours containing either 1 mg (white), 2 mg (yellow), 5 mg (tan) or 10 mg (blue), of the active ingredient terazosin as terazosin monohydrochloride dihydrate. The other ingredients are: lactose, maize starch, purified talc, magnesium stearate, and either no colour (1mg tablet), dye yellow E104, (2mg tablet), dye iron oxide burnt sienna E172, (5 mg tablet) or dye blue E132 (10 mg tablet). What Hytrin Tablets looks like and the contents of the packs Hytrin Tablets are round, flat bevelled tablets embossed with logo and triangular facets on one face and plain on the other and are either; white (1mg), yellow (2mg), tan (5mg) or blue (10mg) They are available in 5 different packs; • The hypertension Starter Pack containing seven 1 mg (white) tablets and twenty-one 2mg (yellow) tablets (4 weeks treatment). • The BPH Starter Pack containing seven 1 mg (white) tablets, fourteen 2 mg (yellow) tablets and seven 5 mg (tan) tablets (4 weeks treatment). • The 2 mg, 5 mg and 10 mg tablet packs each containing 28 tablets (4 weeks treatment).

Marketing Authorisation holder: Amdipharm UK Limited, Dashwood House, 69 Old Broad Street, London, EC2M 1QS, United Kingdom Manufacturer: Famar Italia S.P.A. Via Zambeletti, 25 – 20021 Baranzate, Milano, Italy This leaflet was last revised in March 2024.

Frequently asked questions about Hytrin 10mg Tablets

How do I take Hytrin 10mg Tablets?

Hytrin 10mg Tablets comes as tablet containing 10mg. Always follow the dose your doctor or pharmacist has given you, and read the leaflet that comes with the medicine.

What is the active substance in Hytrin 10mg Tablets?

The active substance in Hytrin 10mg Tablets is terazosin monohydrochloride dihydrate.

Where does this information come from?

This leaflet reproduces the patient information leaflet approved for Hytrin 10mg Tablets, as published on the electronic medicines compendium (emc). The version printed inside your medicine’s packaging is the one that applies to you.

Can I get Hytrin 10mg Tablets without a prescription?

Whether a medicine is available over the counter or on prescription only depends on its licence. Check the leaflet, or ask your pharmacist — they can tell you straight away.

About this leaflet

The text above reproduces the patient information leaflet approved for this medicine, restructured for easier reading.

Medical disclaimer: This page is for information only and does not replace advice from your doctor or pharmacist. Always read the leaflet supplied with your medicine. If you are unwell, call NHS 111; in an emergency, call 999.

Medicines with the same active substance: Terazosin monohydrochloride dihydrate (3 medicines)
See every medicine containing this substance, or browse the full A–Z of active substances.
⚕For healthcare professionals — Summary of Product Characteristics (SmPC)Full SmPC: dosage, interactions, contraindications, warnings+
Technical information intended for healthcare professionals (doctors and pharmacists). The Summary of Product Characteristics (SmPC) is the official document approved by the MHRA/EMA. It does not replace the patient leaflet or a doctor’s advice.

4.1. Therapeutic indications

Orally administered Hytrin is indicated in adults for the treatment of mild to moderate hypertension. It may be used in combination with thiazide diuretics and/or other antihypertensive drugs or as sole therapy where other agents are inappropriate or ineffective. The hypotensive effect is most pronounced on the diastolic pressure. Although the exact mechanism of the hypotensive action of terazosin is not established, the relaxation of peripheral blood vessels appears to be produced mainly by competitive antagonism of post-synaptic alpha-1-adrenoceptors. Hytrin usually produces an initial gradual decrease in blood pressure followed by a sustained antihypertensive action.

Orally administered Hytrin is also indicated in adults as a therapy for the symptomatic treatment of urinary obstruction caused by benign prostatic hyperplasia (BPH). Terazosin is a selective post synaptic alpha-1-adrenoceptor blocker. Antagonism of alpha-1-receptors on prostatic and urethral smooth muscle has been shown to improve urinary tract flow and relieve the urinary obstruction caused by BPH.

4.2. Posology and method of administration

Posology

Hypertension

Adults

Initial dose

1mg before bedtime is the starting dose for all patients and should not be exceeded. Compliance with this initial dosage recommendation should be strictly observed to minimise potential for acute first-dose hypotensive episodes.

Subsequent doses

The single daily dosage may be increased by approximately doubling the dosage at weekly intervals to achieve the desired blood pressure response.

The usual maintenance dose is 2mg to 10mg once daily. Doses over 20mg rarely improve efficacy and doses over 40mg have not been studied.

BPH

Adults

The dose of terazosin should be adjusted according to the patient's response. The following is a guide to administration:

Initial dose

1mg before bedtime is the starting dose for all patients and should not be exceeded. Strict compliance with this recommendation should be observed to minimise acute first-dose hypotensive episodes.

Subsequent dose

The dose may be increased by approximately doubling at weekly or bi-weekly intervals to achieve the desired reduction in symptoms. The maintenance dose is usually 5 to 10mg once daily. Improvements in symptoms have been detected as early as two weeks after starting treatment with terazosin.

At present there are insufficient data to suggest additional symptomatic relief with doses above 10mg once daily.

Transient side effects may occur at each titration step. If any side effects persist, consideration should be given to reducing the dose.

Treatment should be initiated using the Starter Pack and response to treatment reviewed at four weeks.

If administration is discontinued for more than several days, therapy should be re-instituted using the initial dose titration regimen.

Elderly

Pharmacokinetic studies in the elderly indicate that no alteration in dosage recommendation is required.

Renal impairment

Pharmacokinetic studies indicate that patients with impaired renal function need no alteration in the recommended dosages.

Hepatic impairment

The terazosin dose should be titrated with particular caution in patients with impaired liver function since terazosin undergoes extensive hepatic metabolism and is mainly excreted by the biliary tract. As no clinical experience is available in patients with severe hepatic impairment, the use of terazosin is not recommended in these patients.

Paediatric population

Hytrin Tablets are not recommended for use in children. Safety and efficacy in children has not been established.

Method of administration

For oral use

4.3. Contraindications

Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.

Known sensitivity to other alpha-adrenoceptor blockers.

Patients with a history of micturition syncope.

4.4. Special warnings and precautions for use

Terazosin hydrochloride, like other alpha-adrenoceptor blockers, can cause marked lowering of blood pressure, especially postural hypotension and syncope in association with the first dose or first few doses of therapy. A similar effect can be anticipated if therapy is interrupted for more than a few doses and then re-started. Syncope has also been reported with other alpha-adrenoceptor blockers in association with rapid dosage increases or the introduction of another antihypertensive drug. Syncope is believed to be due to an excessive postural hypotensive effect, although occasionally the syncopal episode has been preceded by a bout of severe supraventricular tachycardia with heart rates of 120 to 160 beats per minute.

In clinical trials, the incidence of postural hypotension was greater in BPH patients than in those with hypertension. In these cases, the incidence of postural hypotension events was greater in patients aged 65 years and over (5.6%) than those aged less than 65 years (2.6%).

If administration is discontinued for more than several days, therapy should be re-instituted using the initial dosing regimen.

Before treating the symptoms of benign prostatic hyperplasia (BPH) with alpha-blockers, other causes of impaired urinary flow or urinary symptoms should be excluded. Also where the diagnosis of BPH has been established, it should be confirmed that there is no concomitant obstruction of the upper urinary tract or any signs of infection before treating with terazosin. Patients with benign prostatic hyperplasia, who simultaneously suffer from congestion of the upper urinary tract, chronic urinary tract infection or bladder stones, should not be treated with terazosin.

Terazosin should not be given to patients with bladder overflow, anuria or advanced renal failure.

Due to the risk of an excessive decrease in blood pressure, caution is advised for the concomitant administration of terazosin and thiazides or other antihypertensive medications. If a thiazide diuretic or another antihypertensive medication is added during treatment with terazosin, the terazosin dose must be reduced or the drug discontinued. A new dose-titration is essential. When administering terazosin in addition to other antihypertensives, the dose of the other antihypertensives should be reduced before commencement of therapy and adjusted after discontinuation of terazosin.

Due to the vasodilatory effect of terazosin, it should be administered with caution if the following cardiac conditions are present:

• Pulmonary oedema due to aortic or mitral valve stenosis

• High output cardiac insufficiency

• Right-sided cardiac insufficiency due to pulmonary embolism or pericardial effusion

• Left-sided cardiac insufficiency with low filling pressure

In patients with severe coronary heart disease, a very rapid or excessive decrease in blood pressure can lead to an exacerbation of angina pectoris.

Laboratory Tests: Small but statistically significant decreases in haematocrit, haemoglobin, white blood cells, total protein and albumin were observed in controlled clinical trials. These laboratory findings suggest the possibility of haemodilution. Treatment with terazosin for up to 24 months had no significant effect on Prostate Specific Antigen (PSA) levels.

Caution is also recommended, when terazosin is administered concomitantly with drugs, which may influence hepatic metabolism.

Concomitant use of phosphodiesterase-5-inhibitors (e.g. sildenafil, tadalafil, vardenafil) and terazosin may lead to symptomatic hypotension in some patients. In order to minimise the risk for developing postural hypotension the patient should be stable on the alpha-adrenoceptor blocker therapy before initiating use of phosphodiesterase-5-inhibitors.

The 'Intraoperative Floppy Iris Syndrome' (IFIS, a variant of small pupil syndrome) has been observed during cataract surgery in some patients on or previously treated with tamsulosin. Isolated reports have also been received with other alpha-adrenoceptor blockers and the possibility of a class effect cannot be excluded. As IFIS may lead to increased procedural complications during cataract operation current or past use of alpha-adrenoceptor blockers should be made known to the ophthalmic surgeon in advance of surgery.

Hytrin 10mg Tablets contain lactose

Patients with rare hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption should not take this medicine.

4.5. Interaction with other medicinal products and other forms of interaction

In patients receiving terazosin plus ACE inhibitors or diuretics the proportion reporting dizziness or related side effects was greater than in the total population of terazosin treated patients from clinical trials.Hypotensive effects is enhanced when Terazosin is taken along with adrenergic neurone blockers, alcohol, aldesleukin, alprostadil, anaesthetic (general), angiotensin – II receptor antagonists, antipsychotics, anxiolytics and hypnotics, baclofen, beta-blockers, calcium-channel blockers, clonidine, diazoxide, diuretics, hydralazine, levodopa, monoamine oxidase inhibitors (MAOIs), Methyldopa, Minoxidil, Moxisylyte, Moxonidine, nitrates, sodium nitroprusside, Tizanidine.

Caution should be observed when terazosin is administered with thiazide diuretics or other antihypertensive agents, to avoid the possibility of significant hypotension. When adding terazosin to a diuretic or other antihypertensive agent, dosage reduction and retitration may be necessary.

Terazosin has been given without interaction with analgesics/anti-inflammatories, cardiac glycosides, hypoglycemics, antiarrhythmics, anxiolytics/sedatives, antibacterials, hormones/steroids and drugs used for gout.

Hypotensive effects of terazosin are antagonised by the following: corticosteroids, non-steroidal anti-inflammatory drugs (NSAIDs) and oestrogens.

The hypotensive effect is enhanced when terazocin is given with Phosphodiesterase-5-inhibitors (e.g. sildenafil, tadalafil, vardenafil) (see section 4.4). Avoid giving terazocin for 4 hours after Phosphodiesterase-5-inhibitor administration.

4.6. Fertility, pregnancy and lactation

Pregnancy

Terazosin hydrochloride was not teratogenic in either rats or rabbits when administered at oral doses up to 1330 and 165 times, respectively, the maximum recommended human dose. Fetal resorptions occurred in rats dosed with 480mg/kg/day, approximately 1330 times the maximum recommended human dose. Increased fetal resorptions, decreased fetal weight and an increased number of supernumerary ribs were observed in offspring of rabbits dosed with 165 times the maximum recommended human dose. These findings (in both species) were most likely secondary to maternal toxicity. Although no teratogenic effects were seen in animal testing, the safety of Hytrin use during pregnancy or during lactation has not yet been established. Furthermore, data from animal studies show that terazosin may increase the duration of pregnancy or inhibit labour. Therefore, Hytrin should not be used in pregnancy unless the potential benefit outweighs the risk.

Breast-feeding

It is not known whether terazosin hydrochloride is excreted in breast milk. Because many drugs are excreted in breast milk, caution should be exercised when terazosin hydrochloride is administered to a nursing woman.

Fertility

No data available on human fertility. Animal studies show reduced fertility (see 5.3 Preclinical).

4.7. Effects on ability to drive and use machines

Terazosin tablets have a major influence on the ability to drive and use machines.

Dizziness, light-headedness or drowsiness may occur with the initial dose or in association with missed doses and subsequent reinitiation of Hytrin therapy. Patients should be cautioned about these possible adverse effects and the circumstances in which they may occur and advised to avoid driving or hazardous tasks for approximately 12 hours after initial dose or when the dose is increased.

4.8. Undesirable effects

Hytrin in common with other alpha-adrenoceptor blockers may cause syncope. Syncopal episodes have occurred within 30 to 90 minutes of the initial dose of the drug. Syncope has occasionally occurred in association with rapid dosage increases or the introduction of another antihypertensive agent.

In clinical trials in hypertension, the incidence of syncopal episodes was approximately one percent. In most cases this was believed to be due to an excessive postural hypotensive effect although occasionally the syncopal episode has been preceded by a bout of tachycardia with heart rates of 120 to 160 beats per minute.

If syncope occurs the patient should be placed in a recumbent position and supportive treatment applied as necessary.

Dizziness, light-headedness or fainting may occur when standing up quickly from a lying or sitting position. Patients should be advised of this possibility and instructed to lie down if these symptoms appear and then sit for a few minutes before standing to prevent their recurrence.

These adverse effects are self-limiting and in most cases do not recur after the initial period of therapy or during subsequent re-titration.

Adverse drug effects reported with terazosin from multiple sources including clinical trials and spontaneous reports:

System Organ Class

Frequency

Adverse reaction

Blood and lymphatic system disorder

Not known

Thrombocytopenia

Immune system disorders

Not known

Anaphylactoid reaction

Psychiatric disorders

Not known

Depression, nervousness, anxiety, insomnia

Nervous system disorders

Not known

Dizziness, somnolence, headache, paraesthesia, vertigo

Eye disorders

Not known

Blurred vision, amblyopia, visual impairment, conjunctivitis

Ear and labyrinth disorders

Not known

Tinnitus

Cardiac disorders

Not known

Palpitations, tachycardia, arrhythmia, atrial fibrillation

Vascular disorders

Not known

Postural hypotension, syncope, vasodilatation

Respiratory, thoracic and mediastinal disorders

Not known

Nasal congestion, rhinitis, dyspnoea, sinusitis, bronchitis, epistaxis, flu symptoms, pharyngitis, cold symptoms, cough

Gastrointestinal disorders

Not known

Nausea, abdominal pain, constipation, diarrhoea, dry mouth, dyspepsia, flatulence, vomiting

Skin and subcutaneous tissue disorders

Not known

Pruritus, rash, hyperhidrosis, angioedema

Musculoskeletal and connective tissue disorders

Not known

Back pain, pain in extremity, neck pain, shoulder pain, gout, arthralgia, arthritis, joint disorders, myalgia

Renal and urinary disorders

Not known

Pollakiuria, urinary tract infection and urinary incontinence (primarily reported in post-menopausal women)

Reproductive system and breast disorders

Not known

Libido decreased, erectile dysfunction, priapism

General disorders and administration site conditions

Not known

Asthenia, peripheral oedema, oedema, chest pain, face oedema, pyrexia

Investigations

Not known

Weight increased. Decreased haematocrit, decreased haemoglobin, decreased white blood cell count, decreased total protein and decreased blood albumin (suggestive of haemodilution)

Treatment with terazosin for up to 24 months had no significant effect on prostate specific antigen (PSA) levels.

Reporting of suspected adverse reactions

Reporting of suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme, website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.

4.9. Overdose

Symptoms

Acute hypotension

Management

Cardiovascular support is of first importance. Restoration of blood pressure and normalisation of heart rate may be accomplished by keeping the patient in a supine position. If this measure is inadequate, shock should first be treated with volume expanders and if necessary, vasopressors could then be used. Renal function should be monitored and general supportive measures applied as required. Dialysis may not be of benefit since laboratory data indicate that terazosin is highly protein bound.

🇵🇱 Known in Poland as

Medicines sold in Poland with the same active substance: W Polsce znany jako

⚠ Not the same combination. This medicine contains Terazosin monohydrochloride dihydrate. The products below do not contain exactly the same set of active substances — they are not direct substitutes.

  • Hytrin partial — not the same combinationTerazosinum · taken by mouth
  • Kornam partial — not the same combinationTerazosinum · taken by mouth

Some of these do not contain exactly the same active substances — check each one. The strength, the form and whether you need a prescription can differ. Always ask a pharmacist before you switch. Polish medicines in the UK →

💬 Ask about this leaflet

Ask anything about Hytrin 10mg Tablets. The assistant answers only from this leaflet — if the leaflet does not cover it, it will say so. It does not give medical advice.

Answers come from the patient leaflet published on the electronic medicines compendium (emc). They are not medical advice. Ask a pharmacist or your GP if you are unsure. For urgent help call NHS 111, or 999 in an emergency.

Medicines containing Terazosin monohydrochloride dihydrate

Pharmacies in major towns and cities — see the list
Pharmacies by county and region — see the full list

Browse all 2,009 towns and cities →